Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Elanco Animal Health executive David S. Kinard received a grant of employee stock options, giving him rights to buy 25,620 shares of common stock at an exercise price of $24.09 per share. These options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, and expire on July 1, 2036. Following this grant, Kinard holds 25,620 stock options directly.
Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director K. Anand reported receiving 584.1121 Deferred Stock Units on June 30, 2026. These units were issued at an implied price of $24.61 per unit by deferring her director cash retainer into the company’s Directors’ Deferral Plan.
Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock and will be settled in stock when she leaves the Board. Following this compensation-related award, Anand holds a total of 10,079.5639 Deferred Stock Units directly.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health reported that executive Rajeev A. Modi received a grant of 60.1111 deferred stock units on June 26, 2026, each tied to Company common stock at a reference price of $24.57 per unit. After this award, he holds 9,523.1312 deferred stock units in total.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc reported that President and CEO Jeffrey N. Simmons received a grant of deferred stock units under a compensation plan. The award covers 115.0562 deferred stock units, each linked to one share of Elanco common stock or its cash equivalent at a reference value of $24.57 per unit.
Following this award, Simmons holds a total of 24,657.0048 deferred stock units directly. These units are designed to settle in cash or company shares after his employment ends or in a specified future year, in line with the Executive Deferral and Stock Match Plan, making this a routine, non-market, compensation-related acquisition rather than an open-market purchase.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.0187 deferred stock units tied to Elanco common stock at a reference price of $24.57 per unit. Following this award, he holds 108.8506 deferred stock units, which will settle in cash or shares after employment ends or in a specified future year.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.1514 deferred stock units of Elanco common stock at a reference price of $24.17 per unit. Following this grant, he holds 100.8319 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported a routine compensation-related transaction involving deferred stock units. He received an award of 116.9603 deferred stock units, each tied to the value of one share of Elanco common stock at a reference price of $24.17 per unit.
After this grant, his reported balance of deferred stock units increased to 24,541.9486 units. According to the plan terms, these units will settle in either cash or Elanco common shares after his employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that executive Rajeev A. Modi received a grant of 61.1059 deferred stock units tied to Elanco common stock. Each unit reflects a value of $24.17 per underlying share in the filing.
Following this award, Modi holds a total of 9,463.0201 deferred stock units directly. According to the plan terms, these units will settle in either cash or Elanco common shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported a routine compensation-related award of deferred stock units. He received 8.2608 deferred stock units, each tied to one share of common stock at a reference price of $23.85, bringing his total deferred stock units to 92.6805. These units will be settled in cash or Elanco common stock after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that officer Rajeev A. Modi received a grant of deferred stock units under a company plan. The award covers 61.9258 deferred stock units tied to Elanco common stock at a reference price of $23.85 per unit.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, according to the company’s Executive Deferral and Stock Match Plan. After this grant, Modi holds a total of 9,401.9142 deferred stock units directly.